Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Schizophrenia

• MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
• Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
• Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
• Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
• A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
• Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
• Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
• Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
• Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
• Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
• Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
• Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
• NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
• A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
• A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
• A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
• A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia
• A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
• Metformin Treatment on Cognitive Impairment of Schizophrenia
• Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
• Anti-Inflammatory Challenge in Schizophrenia
• Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
• Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
• Tolerability of MDMA in Schizophrenia
• Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT
• Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
• An Extension Study to a Clinical Study That Will Continue to Evalute the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antisychotic Medication
• A Prospective, Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
• A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
• A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
• Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
• Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
• C-Cog in Early Course Schizophrenia Study
• Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
• Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
• A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
• A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication
• A Randomized Controlled Trial With Rituximab - for Schizophrenia Spectrum Disorder in Adults
• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
• A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
• Phase I of VLT-015 in Patients With Schizophrenia
• A Study of HS-10380 in Chinese Participants
• A Clinical Study That Will Look at an Investigational Medication, SEP-363856 (Called "Study Medication") in Patients With Schizophrenia and Assess Whether it Changes: How the Body Processes (Uses) Glucose (Blood Sugar) ,How Much Insulin the Pancreas
• PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
• Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes
• A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)
• A Clinical Study to Determine Whether an Investigational Medication (SEP-363856) Changes How Long it Takes for Food to Move Through the Stomach Into the Small Intestine in Patients With Schizophrenia. The Study Will Help to Understand Any Effect SEP
• Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
• A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
• Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
• Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
• A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
• Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
• The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
• Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
• Biomarkers in Clozapine-responding Schizophrenia
• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
• Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
• Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
• Ginkgo Biloba Extract in the Treatment of Schizophrenia
• Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
• A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule
• A Placebo-controlled Trial of 15 and 30 mg QD Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
• A Placebo-controlled Trial of 10 and 30 mg QD Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
• The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
• A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study
• Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
• Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
• Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
• Safety and Efficacy of Brilaroxazine (RP5063) in Patients With an Acute Exacerbation of Schizophrenia, Then 52-Week Open-label Extension
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia
• Comparative Bioavailability of Risperidone.
• Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
• Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
• Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
• M1 Schizophrenia PET Study
• Pentoxifylline Add-on Therapy for Schizophrenia
• Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
• D-serine AudRem: R33 Phase
• A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
• Mind to Quit Multisite Trial
• Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
• The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
• Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
• Sodium Nitroprusside in Early Course Schizophrenia
• A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine
• Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
• Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
• Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
• A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
• Relative Bioavailability of LY03010 Compared to Listed Drug
• Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
• Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
• Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia
• Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
• Acetazolamide for Treatment Resistant Schizophrenia
• A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-3)
• Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
• Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
• A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects
• A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
• Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
• PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
• Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
• Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
• Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment
• Monotherapy of an NMDA Enhancer for Schizophrenia
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
• A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
• Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
• Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
• Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
• Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
• Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)
• Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder
• Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients
• A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder
• Pharmacological Modulation of Hippocampal Activity in Psychosis 2
• Psychotherapy for Psychosis, Adverse Events, and Substance Misuse
• Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia
• Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
• SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
• A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
• Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
• Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
• "Extended" (Alternate Day) Antipsychotic Dosing
• Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
• A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
• Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
• Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
• Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
• A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.
• Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
• Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement
• Study of CAD-9303 in Subjects With Schizophrenia
• Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia
• Pharmacologic Modulation of Hippocampal Activity in Psychosis
• Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
• Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia
• Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
• Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia
• Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
• Neurobiological Effects of Oxytocin in Schizophrenia
• Oxytocin and Social Decision Making in Schizophrenia
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
• Safety, Blood Levels and Effects of AUT00201
• Neurobiological Effects of Oxytocin in Schizophrenia - Imaging Study
• A Study of Staccato Loxapine (ADASUVE®) for Inhalation
• A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
• Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
• A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
• Bazedoxifene -Treatment for Women With Schizophrenia
• A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
• The Phosphodiesterase Inhibitor Pentoxifylline as an Adjuvant in Treatment of Negative Symptoms in Chronic Schizophrenia
• Estradiol as add-on to Antipsychotics
• A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
• The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
• A Study of Paliperidone Palmitate 6-Month Formulation
• A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
• L-arginine Study for Persistent Symptoms of Schizophrenia
• A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
• Imaging Synapses With [11C] UCB-J in the Human Brain
• A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
• Anti-inflammatories and Adolescent Schizophrenia
• The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
• Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
• Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
• Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
• FEcal Microbiota Transplantation
• The Sub-Sero Study
• Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
• Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
• Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
• Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
• Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
• Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
• Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain
• A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
• A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
• Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
• Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
• Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
• Persistence Targeted Smoking Cessation in Schizophrenia
• Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
• Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
• Telmisartan Pilot Study on Treatment Resistant Schizophrenia
• Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia
• A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
• Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
• Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
• Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
• Comparison of Ketamine Combine Propofol vs Propofol Anesthesia in Schizophrenia Electroconvulsive Therapy
• Treating Smokers With Mental Illness
• Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
• This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
• ITI-007 (Lumateperone Tosylate) for Schizophrenia
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
• Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
• Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia
• Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia
• Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
• Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
• Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
• Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
• Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
• Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
• The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia
• A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
• Study of Efficacy of PEAR-004 in Schizophrenia
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
• Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
• A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
• D-serine Augmentation of Neuroplasticity
• Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
• BXCL501 for Agitation in Schizophrenia
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
• Cognitive Effects of Nimodipine in Patients With Schizophrenia
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
• CVN058 Effect on Mismatch Negativity in Schizophrenics
• Effects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Possible Mechanisms
• Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
• A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
• A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
• Prebiotic Treatment in People With Schizophrenia
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
• Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance
• A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
• A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
• Research Into Antipsychotic Discontinuation and Reduction Trial
• A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
• Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
• Comparative Bioavailability of Risperidone
• Brexpiprazole Study
• Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
• Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
• Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
• Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
• Substance Misuse To Psychosis for Stimulants
• Touchscreen-based Cognitive Tests in Healthy Volunteers
• A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
• Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
• Mindfulness-based Social Cognition Training for Psychosis (SocialMind): A Feasibility Study
• A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
• Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women
• Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
• A Study of Lurasidone HCl in Subjects With Schizophrenia
• A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
• A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder
• MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).
• Add-on Methotrexate for the Treatment of Schizophrenia
• A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia
• A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
• A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
• A Study of Paliperidone Palmitate 6-Month Formulation
• The Norwegian Prednisolone in Early Psychosis Study
• Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients
• Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
• Glutamate Reducing Interventions in Schizophrenia
• A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
• Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)
• Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
• Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
• Aripiprazole IM Depot for Chinese Patients With Schizophrenia
• PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
• Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
• Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
• HDAC Inhibitor Augmentation to Clozapine
• Berberine Treat Metabolic Syndrome in Schizophrenia
• Target Engagement and Response to Oxytocin
• Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
• Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
• Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
• Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
• Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
• Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
• Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia
• Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
• "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
• Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
• Levetiracetam in Early Psychosis
• Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
• Role of Vitamin D Supplementation in Schizophrenia
• An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adult
• Inflammatory Response In Schizophrenia
• Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
• Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
• Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
• An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)
• Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
• Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
• Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
• Sodium Butyrate For Improving Cognitive Function In Schizophrenia
• Berberine as Adjuvant Treatment for Schizophrenia Patients
• Clinical Trial of AVL-3288 in Schizophrenia Patients
• An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
• Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
• Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
• A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
• Minocycline and Tobacco Craving in Smokers With Schizophrenia
• Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
• A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
• Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
• Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
• Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients
• The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
• A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
• Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
• Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
• The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
• The Optimal Treatment for Treatment-resistant Schizophrenia
• Enhancing Recovery in Early Schizophrenia
• Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
• E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia
• Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia
• The Role of Nitric Oxide in Cognition in Schizophrenia
• Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
• Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
• [18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
• Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
• Tocilizumab in Schizophrenia
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
• A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
• Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients
• The Impact of Caffeine on Cognition in Schizophrenia
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
• Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
• Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
• A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
• Sulforaphane to Reduce Symptoms of Schizophrenia
• Topiramate and Schizophrenia: Effects on Weight and Psychopathology
• A Phase 1 Safety Study in Adults With Schizophrenia
• Siltuximab in Schizophrenia
• MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
• Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
• Safety and Tolerability of Risperidone Implants
• Glutamate, Learning, and Working Memory
• Single Ascending Dose Study of RBP-7000
• First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
• Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
• Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
• Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
• Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
• Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
• Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
• A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
• Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
• Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
• Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
• A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
• Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine
• Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
• PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
• Carnosine and Cognitive Training in Schizophrenia
• Aspirin in Young Psychotic Patients
• Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
• Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
• A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
• Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression
• Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia
• Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
• The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
• Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
• Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
• Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
• A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
• Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
• A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
• A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
• The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.
• A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
• Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
• NRX-1074 in Early Course Schizophrenia
• Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
• Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana
• Safety, Blood Levels and Effects of AUT00206
• Antipsychotics and Risk of Hyperglycemic Emergencies
• Adult Oxytocin Study
• Guideline vs Usual Treatment in Schizophrenic Adolescents
• Oxytocin MEG Study
• Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
• Adult Study Oxytocin - Behavioral
• A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
• Adult Study Oxytocin - fMRI
• Nicotinic Receptors and Schizophrenia
• Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
• Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
• DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
• Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
• Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
• Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
• Role Functioning Changes NOS
• Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
• Cannabidiol Treatment in Patients With Early Psychosis
• Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
• Target Engagement for Oxytocin: Dose Ranging Study
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
• A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
• Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
• Linagliptin and Mesenchymal Stem Cells: A Pilot Study
• A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
• 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
• Antipsychotic Induced Structural and Functional Brain Changes
• A Pharmacokinetic Study of Paliperidone ER
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
• Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination
• Neuroendocrine and Metabolite Substrates in Schizophrenia
• Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia
• A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
• Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
• Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
• Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
• Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
• Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)
• Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
• Pharmacovigilance in Gerontopsychiatric Patients
• Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
• Adjunctive Vortioxetine in Schizophrenia
• Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
• Pan European Collaboration on Antipsychotic Naïve Schizophrenia II
• Long-term Study of DSP-5423P in Patients With Schizophrenia
• Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
• Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
• Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
• An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
• Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
• Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
• Dyad Oxytocin Study (DOS)
• Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients
• Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
• Confirmatory Study of DSP-5423P in Patients With Schizophrenia
• Study of the Effect of Dosing on Clozapine Levels
• A Trial to Assess the Antipsychotic Efficacy of ITI-007
• Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
• Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults
• Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
• Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
• Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism
• Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
• Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
• Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
• Pharmacokinetic Study of MIN-101 in Healthy Subjects
• Novel Smoking Cessation Drug for Schizophrenia
• A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
• A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
• Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
• Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
• Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
• Lurasidone Effects on Tissue Glutamate in Schizophrenia
• Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
• A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
• Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
• An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
• MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
• The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study
• Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
• A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
• Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
• A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
• D-serine and Cognitive Remediation in Schizophrenia
• F17464 in Acute Schizophrenia Trial
• Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
• European Long-acting Antipsychotics in Schizophrenia Trial
• Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia
• The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics
• Effects of Metformin and Fish Oil on Treatment With Clozapine
• Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia
• Minocycline Augmentation to Clozapine
• Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
• Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
• Probing the Cannabinoid System in Individuals With a Family History of Psychosis
• Association of Amisulpride Response in Schizophrenia With Brain Image
• Bioavailability of LY03004 and Risperdal® Consta®
• A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
• Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
• Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
• Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
• RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
• Bioequivalence Fasting Study in Patients
• Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
• Tryptophan MRI in People With Schizophrenia and Healthy Controls
• Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia
• Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
• Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
• Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
• Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
• Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Sta
• Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
• Glutamate, Brain Connectivity and Duration of Untreated Psychosis
• The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia
• A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
• Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
• Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
• A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
• Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
• A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
• A Clinical Trial of Lurasidone in Treatment of Schizophrenia
• Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
• Simvastatin Addition for Patients With Recent-onset Schizophrenia
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
• Antipsychotic Effects of Oxytocin
• Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
• D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
• A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
• Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
• Investigator Initiated Study - Asenapine Early Psychosis
• Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
• Aripiprazole Once-monthly in Patients With Schizophrenia
• A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
• Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
• Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study
• Bio-equivalence Study Between SAPHRIS and Asenapine
• A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia
• Famotidine in Schizophrenia
• Linagliptin in Schizophrenia Patients
• A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
• A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
• A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
• A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
• Effects of Varenicline on Plasticity in Schizophrenia
• Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
• A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
• A PET Study With RO5545965 in Healthy Male Volunteers
• Pediatric Open-Label Extension Study
• Antipsychotic Effects on Brain Function in Schizophrenia
• Translational Neuroscience Optimization of GlyT1 Inhibitor
• Pediatric Schizophrenia Efficacy and Safety Study
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
• Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
• Phosphatidylcholine Supplementation in Infants
• A Study of ALKS 3831 in Adults With Schizophrenia
• Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
• An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
• An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
• Safety and Tolerability of BI 409306 in Patients With Schizophrenia
• Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
• N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
• Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
• Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
• The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
• A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
• Naltrexone for Antipsychotic-Induced Weight Gain
• The Effect of Paliperidone Palmitate in Schizophrenia
• An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
• PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
• Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia
• Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects
• Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia
• Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
• The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
• Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
• A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
• Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
• Lurasidone Low-Dose - High-Dose Study Study
• A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients
• Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
• A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
• Brexpiprazole in Patients With Schizophrenia
• Brexpiprazole in Patients With Acute Schizophrenia
• Minocycline for Schizophrenia
• Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
• Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia
• Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
• Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
• Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
• Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
• Omega-3 Dietary Supplements in Schizophrenia
• Fingolimod in Schizophrenia Patients
• Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
• Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
• SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
• Vitamin D for Schizophrenia
• Oxytocin and CBSST for People With Schizophrenia
• A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
• Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
• Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
• A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
• Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
• A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia
• Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
• A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
• Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
• Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
• Kuvan in People With Schizophrenia and Schizoaffective Disorder
• Oxytocin as Adjunctive Therapy for Schizophrenia
• An Open-Label Trial of Tocilizumab in Schizophrenia
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
• A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
• Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
• A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
• A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
• Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
• Clinical Benefits of Seroquel XR in Anxiety Disorder
• A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
• Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
• Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
• Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
• Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia
• An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
• Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
• A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
• The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine
• A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
• Multicenter, Open-label, Safety and Tolerability Study
• An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
• Effects of Eszopiclone on Sleep and Memory in Schizophrenia
• Clozapine for Cannabis Use in Schizophrenia
• Antipsychotic Augmentation With L-Dopa
• Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets
• A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
• Long-Term Study of MP-214 in Patients With Schizophrenia
• A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
• A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
• A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
• Safety and Efficacy of MP-214 in Patients With Schizophrenia
• Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia
• Antipsychotic Effects of Oxytocin
• Lurasidone Pediatric Pharmacokinetics Study
• Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
• A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
• A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia
• Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
• A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
• Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
• Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
• A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
• A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
• A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia
• Randomized Double Blind Placebo Control Study in Patients With Schizophrenia
• Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
• Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
• Melatonin for Prevention of Metabolic Side Effects of Olanzapine
• A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
• A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
• Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study
• Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
• Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)
• A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia
• Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia
• Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
• High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
• Oxytocin as Adjunctive Treatment of Schizophrenia
• 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
• 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
• First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
• Alleviating the Metabolic Side Effects of Antipsychotic Medications
• A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
• A Long-Term Study of JNS007ER in Patients With Schizophrenia
• Minocycline Augmentation in Schizophrenia
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
• Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
• Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen
• Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
• Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
• Once-Daily Asenapine for Schizophrenia
• Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia
• A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
• A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
• A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
• A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
• Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital
• Ginkgo Biloba Extract for Schizophrenia
• Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
• A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
• Pharmacological Approach to Improve the Outcome of Social Cognition Training
• Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
• Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
• Anti-Inflammatory Treatment of Schizophrenia
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
• Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
• Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia
• Study of a Novel Antipsychotic ITI-007 in Schizophrenia
• Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
• A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
• The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
• Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
• A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
• RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
• Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
• A Long-Term Study in Schizophrenia
• Lurasidone Extended Use Study
• Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
• N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
• A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
• Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia
• High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia
• Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
• A Long-term Trial of OPC-34712 in Patients With Schizophrenia
• Optimisation of Antipsychotic Drug Use in Older People
• A Physical Dependence Study in Schizophrenia
• Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
• A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
• POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
• Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
• Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
• Bergen Psychosis Project 2 - The Best Intro Study
• PEARL Schizophrenia Maintenance
• Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
• Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
• Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
• Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
• A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
• Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
• A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
• Risperidone and Desipramine in Alcohol Use and Schizophrenia
• Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine
• Nicotinic Receptors and Schizophrenia
• Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients
• F-18 Altanserin PET Study of Patients Receiving Clozapine
• Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
• Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
• Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)
• Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
• Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
• Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia
• DAAOI-1 Treatment for Treatment-resistant Schizophrenia
• A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
• Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants
• First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
• Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
• Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
• A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects
• To Rescue Cognition With Valaciclovir
• Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
• Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
• Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
• A Study of Safety and Tolerability in Subjects With Schizophrenia
• N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
• Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
• Add On Treatment for Cognitive Deficits in Schizophrenia
• The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
• Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
• A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
• Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
• Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
• Nicotine Effects on Endophenotypes of Schizophrenia
• Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
• A Study of LY2140023 in Patients With Schizophrenia
• Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients
• Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
• A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
• An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
• Safety and Efficacy of Zicronapine in Patients With Schizophrenia
• Relapse Prevention Study in Patients With Schizophrenia
• Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
• Different Safety Profile of Risperidone and Paliperidone Extended-release
• Paliperidone Palmitate Flexible Dosing in Schizophrenia
• Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
• Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
• Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects
• Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
• Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
• A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
• GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
• Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)
• Optimization of Treatment and Management of Schizophrenia in Europe
• Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
• Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
• A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
• A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
• A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
• A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
• Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
• SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
• A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
• Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
• Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
• A Repeat Dose Positron Emission Tomography Study With GSK1144814
• Switching to Iloperidone From Other Antipsychotics in Schizophrenia
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
• Effectiveness of Ziprasidone for Patients With Schizophrenia
• Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
• A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
• A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
• A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
• Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
• Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
• Add-On Therapy to Risperidonein Schizophrenia
• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
• Antipsychotics and Gene Expression in Soft Tissues
• Salsalate for Insulin Resistance in Schizophrenia
• Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
• Metformin for Weight Loss in Schizophrenia
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
• Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
• The Effect of Ketamine on Attentiveness
• Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
• Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
• Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning
• Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
• 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
• Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
• A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
• Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
• Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
• A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
• A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
• Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
• Effects of Ketamine and Risperidone on Cognition
• An Open Trial of Cysteamine Treatment in Schizophrenia
• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
• A Comparison of Long-acting Injectable Medications for Schizophrenia
• Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study
• An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
• A Long-Term, Open-Label, Study on Schizophrenia
• A Study in Schizophrenic Patients
• Clozapine and Olanzapine Treatment of Aggression
• Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia
• Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
• Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
• A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
• Varenicline and Smoking Cessation in Schizophrenia
• A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate
• Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
• Long-term Study of Cariprazine in Patients With Schizophrenia
• Safety and Efficacy of Cariprazine in Schizophrenia
• Safety and Efficacy of Cariprazine in Patients With Schizophrenia
• Ketamine Challenge Study With JNJ-40411813
• A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
• Effects of Galantamine on Cognition
• 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
• Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
• Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia
• Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects
• A Study in Schizophrenia Patients
• Is MS14 Helpful in Schizophrenia?
• Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
• Digoxin Drug-Drug Interaction With Lurasidone HCl
• Midazolam Drug-Drug Interaction Study With Lurasidone HCl
• The Bioequivalence Of Two Different Lurasidone Formulations In Patients
• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
• Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype
• Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
• Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
• Lithium Drug-Drug Interaction Study With Lurasidone HCl
• Quetiapine XR in Schizophrenic Patients
• Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia
• A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
• Standard Comprehensive Intervention to Treat First-episode Schizophrenia
• A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule
• Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia
• A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
• A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
• A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
• Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
• Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
• The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia
• Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
• DECIFER: Depression and Citalopram In First Episode Recovery
• Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women
• Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
• Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
• Oxytocin Treatment of Schizophrenia
• InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
• Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
• Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
• Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
• A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
• Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia
• Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
• An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
• Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
• Vitamin D Supplementation in Psychiatric Illnesses
• TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
• Oral Aripiprazole Open-Label Rollover Study
• Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia
• Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia
• An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
• Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
• The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
• Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
• Effects of Delta-9-THC and Iomazenil in Healthy Humans
• Study in Adolescents With Schizophrenia or Bipolar Disorder
• Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
• A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
• Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
• A Study of Olanzapine in Patients With Schizophrenia
• Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
• Once Weekly D-cycloserine for Schizophrenia
• D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
• Huperzine for Cognitive and Functional Impairment in Schizophrenia
• D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
• Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
• Nicotinic Receptors and Schizophrenia
• Lamictal TM, Haloperidol Decanoate in Schizophrenia
• 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
• Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
• Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
• Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
• A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patient
• Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)
• Oculomotor and Spatial Cognition Deficits in Schizophrenia
• Role of Anti-Inflammatory Agents in Patients With Schizophrenia
• A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
• Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
• Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
• Polypharmacy in Clozapine-resistant Schizophrenia
• Evaluation Study of New Compounds With Potential Use in Schizophrenia
• A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia
• Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
• Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
• Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
• A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
• A Bioequivalence Study of 15 mg ER OROS Paliperidone
• A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers
• A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder
• Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
• A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia
• Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)
• Oxytocin and Social Cognition in Schizophrenia
• Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
• Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
• A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia
• Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
• Sertindole in Asian Patients With Schizophrenia
• Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
• Study of CYR-101 in Patients With Schizophrenia
• Bifeprunox Extension to Extension Study in Patients With Schizophrenia
• Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
• Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
• Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
• Seroquel XR in Adults With Schizophrenia
• Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)
• Risperidone Maintenance Treatment in Schizophrenia
• A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
• A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
• A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
• A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
• Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
• Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia
• Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
• Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
• Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.
• A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
• Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
• D-serine for the Schizophrenia Prodrome
• Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
• Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
• An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
• Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
• 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
• A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
• Biomarkers in Schizophrenia
• The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
• D-serine Monotherapy for Schizophrenia
• The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.
• Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia
• Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
• Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
• Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
• Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia
• Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
• A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
• A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
• A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
• A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
• Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
• Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
• A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
• A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
• A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
• A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
• A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
• A Study of the Dose Proportionality of Extended Release Paliperidone
• A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville
• Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
• Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
• Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
• Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
• Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
• Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
• Efficacy of Lu 31-130 in Patients With Schizophrenia
• Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
• Efficacy of Lu 31-130 in Patients With Schizophrenia
• Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
• Efficacy Study on Cognitive Functions in Schizophrenic Patients
• Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
• Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
• PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
• Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia
• Exploratory Cognition Study of Sertindole in Patients With Schizophrenia
• Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.
• Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
• Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)
• 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
• One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
• A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
• Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
• Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
• Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol
• A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
• Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
• Minocycline for the Treatment of Early-Phase Schizophrenia
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
• Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
• An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
• Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
• A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
• Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
• A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
• Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
• L-arginine in Treatment as Usual in Schizophrenia
• Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
• Anticholinergic Burden in Schizophrenia
• Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
• Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia
• Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
• Modafinil Effects on Cognition in Schizophrenia Patients
• Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
• Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
• Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
• Efficacy of Bifeprunox in Patients With Schizophrenia
• Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
• INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia
• Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
• Study to Demonstrate Cognitive Enhancing Effects of BF2.649
• Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
• Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects
• Biomarker Study of Acamprosate in Schizophrenia
• Phase IIA Study in Patients With Schizophrenia
• Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
• A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia
• FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
• Schizophrenic Patients in Integrated Care
• Cardio Risk of Acute Schizophrenia Olanzapine Duke
• Extract of Ginkgo Biloba and Tardive Dyskinesia
• Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
• A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
• Effects of Oxytocin Nasal Spray on Social Affiliation
• Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
• Treatment of Neuroleptic Induced Acute Akathisia With Trazodone
• Efficacy of Bifeprunox in Patients With Schizophrenia
• Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
• Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
• A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
• A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
• A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
• A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
• A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
• Effect of Single Dose Intranasal Insulin On Cognitive Function
• Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
• Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
• A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
• Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.
• A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
• A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
• A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
• Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
• A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
• A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
• Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
• Quetiapine Extended Release Depression Symptoms
• A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
• Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia
• Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
• Ethyl-EPA Treatment of Prodromal Patients
• A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
• Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia
• The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients
• Staccato Loxapine in Agitated Patients With Schizophrenia
• Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
• Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
• Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
• A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
• Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
• Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail
• A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
• Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
• The Effect of Plasma Osmolality on Brain Glutamate
• Add-on Simvastatin in Schizophrenia Trial
• Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
• A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
• Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
• Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
• Sodium Oxybate in Schizophrenia With Insomnia
• A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
• Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
• Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
• Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
• Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
• Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
• Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
• Treatment of Schizophrenic Patients With Ziprasidone
• Intranasal Insulin Treatment in Patients With Schizophrenia
• A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia
• First Episode Schizophrenia and Cannabis-Related Disorder Study
• Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
• A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
• A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
• Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
• Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects
• An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
• Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
• Study Evaluating Vabicaserin in Subjects With Schizophrenia
• Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
• Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
• A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
• Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
• Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients
• Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
• Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
• Varenicline Effects In Schizophrenic Smokers
• The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
• The Effects of Rimonabant, on Weight and Metabolic Risk Factors
• Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
• Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents
• Study Comparing Bioavailability of Oral Formulations of Vabicaserin
• High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
• Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
• Schizophrenia Sensory Gating Deficit With Quetiapine
• Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
• Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
• Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
• Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
• Metabolic Profile and Anthropometric Changes in Schizophrenia
• Early Detection and Intervention for the Prevention of Psychosis
• Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
• β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
• First Time in Human Study With GSK1018921
• An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
• Oxygen Therapy in Schizophrenia
• An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
• The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia
• A Study for Patients With Schizophrenia
• Health Evaluation of Abilify Long-term Therapy
• A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients
• Glucose and Lipid Metabolism on Antipsychotic Medication
• Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
• Systematic Evaluation of Antiviral Medication in Schizophrenia
• Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
• Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
• Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study
• An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
• Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
• A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
• Oxytocin Add on Study for Stable Schizophrenic Patients
• MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
• Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects
• A Multicenter Study of NAP (AL-108) in Schizophrenia
• Treatment Study for Cognitive Deficits in Schizophrenia
• Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder
• A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.
• Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
• Quality of Life (QOL) in Female Patient With Schizophrenia
• The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
• A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
• Antipsychotic Polypharmacy in Schizophrenia
• Varenicline Adjunctive Treatment in Schizophrenia
• Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
• Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
• ACP-104 in Acutely Psychotic Subjects With Schizophrenia
• The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
• Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
• Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
• Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
• FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
• Weight Gain Management in Patients With Schizophrenia
• Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia
• Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
• Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia
• Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
• A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia
• MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
• Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
• Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
• An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
• Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
• The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
• Metabolic Signatures and Biomarkers in Schizophrenia
• Donepezil Double Blind Trial for ECT Memory Disfunction
• Galantamine for Cognitive Deficits in Schizophrenia
• Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
• Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
• RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice
• Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
• Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
• Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
• Efficacy of Selegiline in Negative Symptoms of Schizophrenia
• Escitalopram in Schizophrenia in OCD- Open Label Study
• A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia
• Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
• Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
• Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
• Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)
• Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers
• Safety, PK and PD Study in Healthy Male Japanese Subjects
• Diabetes in Neuropsychiatric Disorders
• Staccato Loxapine Single Dose PK
• Zyprexa and Task Engagement in Schizophrenia
• Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
• Amisulpride in Schizophrenic Acute Phase Patients
• Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
• Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
• Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia
• Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
• Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
• Effects of Atomoxetine on Cognitive Function in Schizophrenia
• Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
• Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
• Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward
• Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
• An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
• Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812
• Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
• Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
• Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
• Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
• High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
• Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
• PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
• Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
• A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
• Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
• Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia
• Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
• Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
• An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
• Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.
• A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
• A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
• Treatment of Refractory Schizophrenia With Riluzole
• Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
• Efficacy of Pimozide Augmentation for Clozapine Partial Response
• Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
• The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
• Quetiapine and the Dopaminergic Epigenetic Control
• Staccato Loxapine in Agitation (Proof of Concept)
• Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
• Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
• Study Evaluating Bifeprunox in Patients With Schizophrenia.
• Open Label Extension Study of Bifeprunox
• SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
• Tetrabenazine for Partial Responders
• Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
• Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
• A Definitive Estrogen Patch Study (ADEPT)
• The New Strategy for Pharmacological Treatment in People With Schizophrenia
• A Placebo-Controlled, Cross-Over Trial of Aripiprazole
• Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
• A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
• Clinical Trial of Dipyridamole in Schizophrenia
• Switch Study of Existing Atypical Antipsychotics to Bifeprunox
• Augmenting Clozapine With Sertindole - SERCLOZ
• Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
• Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
• Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
• Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
• Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
• Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
• Antipsychotic Therapy and First Episode
• Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
• Amisulpride in Schizophrenic Patients
• Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
• Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
• Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
• Effect on Cognitive Function of a Treatment With Aripiprazole
• Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
• Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
• Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
• Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
• Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet
• Safety and Effectiveness of D-serine in Schizophrenia
• Galantamine for Cognition in People With Schizophrenia
• Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia
• Smoking Relapse Prevention in Schizophrenia
• Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
• Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
• Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
• A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
• Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine
• Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia
• Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
• Optimizing Response in Psychosis Study
• Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
• Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
• Specialized Treatment Early in Psychosis (STEP)
• A Clinical Trial on the Antipsychotic Properties of Cannabidiol
• Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility
• Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
• Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
• Identification and Treatment of the Liability to Develop Schizophrenia
• Effect of Quetiapine on Negative Symptoms and Cognition
• Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
• SWitching to Abilify Trial (SWAT)
• Fast Titration in the Treatment of Schizophrenia, Taiwan
• Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
• Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
• A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
• Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
• Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
• High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
• A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
• The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
• A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
• A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
• Glycine vs Placebo for the Schizophrenia Prodrome
• Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics
• Risperidone Augmentation in Patients With Schizophrenia
• Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
• Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
• Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
• Study of Amantadine for Weight Stabilization During Olanzapine Treatment
• A Registry of Treatment Adherence for Patients With Schizophrenia
• Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
• Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
• Risperidone LA Heathcare Resource Study
• CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
• An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
• SPECT Study With SB-773812 In Schizophrenic Patients
• Glycine Treatment of Prodromal Symptoms
• Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
• Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
• ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
• SB-773812 Administered In Adults With Schizophrenia
• Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
• An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
• A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication
• Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
• Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
• Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients
• Safety and Efficacy of Seroquel in First Episode Schizophrenia
• Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
• A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
• A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
• A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
• Folate Supplementation in Schizophrenia
• A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
• A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
• An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
• A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
• Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
• SOLIACS: Solian Solution in the Acute Setting
• Side Effects of Newer Antipsychotics in Older Adults
• A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
• Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
• Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
• A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
• Schizophrenia Trial of Aripiprazole
• Aripiprazole Treatment of Prodromal Patients
• Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
• D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
• D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
• A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
• Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-ac
• A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
• Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
• Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia
• Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
• Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
• A Switch Study of BMS-337039 in Schizophrenic Out-patients
• Efficacy of Galantamine to Treat Schizophrenia
• Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
• Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
• Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
• Patient-reported Outcomes in the Treatment of Schizophrenia
• Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)
• Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
• Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
• Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
• The Effects of Aripiprazole on Patients With Metabolic Syndrome
• Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
• The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
• A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
• A Comparative Study of New Medications for Psychosis in Adolescents
• Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
• PREvent First Episode Relapse (PREFER)
• Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
• Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
• Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
• Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
• A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
• A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
• A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
• A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
• D-Serine Monotherapy for Schizophrenia
• Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
• Seroquel on Glucose Metabolism
• Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
• Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
• Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
• Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
• A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
• A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
• A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia
• The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
• Abilify Therapy for Reducing Comorbid Substance Abuse
• Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
• Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
• Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
• Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
• The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
• Clinical Estradiol Trial in Women With Schizophrenia
• The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
• Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia
• SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
• A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
• Janssen - Glucose Regulation/Risp/Olanz
• Pfizer/IVGTT/Ziprasidone/Olanzapine
• Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
• Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
• Improving Work Outcome in People With Recent-onset Schizophrenia
• Indicated Prevention of Psychotic Disorders With Low-dose Lithium
• Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
• Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
• Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
• In-Patient Study In Schizophrenic Patients
• Valproate in Late Life Schizophrenia
• Bifeprunox in the Treatment of Schizophrenia
• Bifeprunox in the Treatment of Schizophrenia
• Entacapone Augmentation for Schizophrenia
• Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
• Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
• Clozapine IM and Aggression in Schizophrenic Patients
• Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
• Treatment of Mania Symptoms With Drug Therapy
• Cognition, Functioning and Quality of Life
• Treating Schizophrenia by Correcting Abnormal Brain Development
• Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
• Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
• Serotonin 1A Agonists and Cognition in Schizophrenia
• Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
• L-carnosine for Schizophrenia
• Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
• Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
• Pregnenolone in the Management of Schizophrenia Patients
• Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
• Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
• Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
• Aripiprazole Treatment of the Prodrome
• Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
• Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
• Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
• Alcoholism and Schizophrenia: Effects of Clozapine
• Determining Metabolic Effects of Valproate and Antipsychotic Therapy
• Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
• Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
• An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
• Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
• New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
• Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
• 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
• Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
• One Year Drug Treatment in First-Episode Schizophrenia
• Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
• Optimization of Acute Treatment in First Episode Schizophrenia
• Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
• Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
• Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)
• Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
• Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
• A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
• Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
• A First In Human Study Of PF-00184562 In Healthy Volunteers
• To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
• Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
• Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
• Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
• Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
• Energy Homeostasis Under Treatment With Atypical Antipsychotics
• The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
• Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
• Naltrexone Treatment of Alcohol Abuse in Schizophrenia
• Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
• Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
• Mozart Relapse Study
• Bexarotene Treatment in Schizophrenia
• To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
• Creatine Treatment in Psychiatric Disorders
• Treatment of Acute Schizophrenia With Vitamin Therapy
• Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
• Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
• Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
• Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
• Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
• IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
• Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
• Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
• Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
• Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
• Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
• A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia
• Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
• Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
• A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
• The Effects of Risperidone and Olanzapine on Thinking
• Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients
• Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
• Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
• Aripiprazole Open-Label, Safety and Tolerability Study
• Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
• Aripiprazole in Adolescents With Schizophrenia
• Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
• Aripiprazole Oral Acceptability Trial
• Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
• Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
• Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
• Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
• Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
• Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
• Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
• A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
• A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
• A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
• Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
• Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
• Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
• Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
• Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
• Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
• A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.
• Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
• Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
• Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
• Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
• Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
• A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
• Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
• Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
• Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
• Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
• Clinical Study Of Schizophrenia in Both Men and Women
• Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
• Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
• Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
• Effects of Modafinil on Brain Function in Patients With Schizophrenia
• Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
• Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
• Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
• Schizophrenia Study In Adults
• Treating Drug-Resistant Childhood Schizophrenia
• Antidepressant Treatment in Older Adults With Schizophrenia
• Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1
• Switching Medication to Treat Schizophrenia
• The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
• Clinical Trial of Tolcapone for Cognition in Schizophrenia
• A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
• Safety and Tolerability Study of Drug to Treat Schizophrenia
• Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
• Broad Effectiveness: Study With Aripiprazole
• Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
• Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
• A Comparison of Seroquel vs. Risperidone in Schizophrenia
• CAFE Comparison of Atypicals in First Episode of Psychosis
• Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
• A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
• The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
• 5HT3 Antagonism and Auditory Gating in Schizophrenia
• Antipsychotic Response in Schizophrenia
• Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
• CATIE- Schizophrenia Trial
• To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
• Glucose Regulation During Risperidone and Olanzapine Treatment
• Glycine to Treat Psychotic Disorders in Children
• Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
• Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
• Treatment for First-Episode Schizophrenia
• Glycine and D-Cycloserine in Schizophrenia
• Trial of D-Cycloserine in Schizophrenia